Skip to main content
. 2018 Mar 23;144(6):1143–1154. doi: 10.1007/s00432-018-2630-8

Table 3.

Clinicopathological characteristics of the propensity score-matched cohort (n = 722)

Variables Transfusion group (n = 361) Non-transfusion group (n = 361) P value
Gender (males) 225 (62.3%) 229 (63.4%) 0.758
Age (years) 57.15 ± 10.92 55.76 ± 11.43 0.096
Body Mass Index (kg/m2) 21.26 ± 2.74 21.24 ± 2.77 0.895
ASA score 0.067
 1 48 (13.3%) 46 (12.7%)
 2 256 (70.9%) 233 (64.5%)
 3 54 (15.0%) 77 (21.3%)
 4 3 (0.8%) 5 (1.4%)
Smoking history 136 (37.7%) 125 (34.6%) 0.394
Any comorbidities 115 (31.9%) 119 (33.0%) 0.750
History of abdominal surgery 40 (11.1%) 37 (10.2%) 0.718
Neo-adjuvant chemotherapy 26 (7.2%) 16 (4.4%) 0.112
Pre-operative white blood cell count (× 109/L) 5.86 ± 1.87 6.10 ± 1.73 0.080
Pre-operative lymphocyte count (× 109/L) 1.62 ± 0.74 1.66 ± 0.65 0.416
Pre-operative albumin (g/L) 36.39 ± 4.87 36.91 ± 4.96 0.154
Pre-operative hemoglobin (g/L) 91.19 ± 23.99 119.98 ± 17.38 < 0.001
Complication due to the tumora 147 (40.7%) 147 (40.7%) 1.000
Operation method 0.091
 Open 322 (89.2%) 335 (92.8%)
 Laparoscopy 39 (10.8%) 26 (7.2%)
Type of resection 0.203
 Subtotal gastrectomy 260 (72.0%) 275 (76.2%)
 Total gastrectomy 101 (28.0%) 86 (23.8%)
Combined multi-organ resection 52 (14.4%) 50 (13.9%) 0.831
Tumor size (cm) 4.77 ± 2.11 4.86 ± 2.02 0.544
Tumor location 0.441
 Upper 43 (11.9%) 40 (11.1%)
 Middle 92 (25.5%) 75 (20.8%)
 Lower 210 (58.2%) 228 (63.2%)
 Diffuse 16 (4.4%) 18 (5.0%)
pTNM stageb 0.977
 I 55 (15.2%) 43 (11.9%)
 II 58 (16.1%) 74 (20.5%)
 III 248 (68.7%) 244 (67.6%)
Intra-operative blood loss (mL) 248 ± 177 212 ± 90 0.001
Operation time (min) 211.78 ± 58.61 216.61 ± 45.50 0.199
Post-operative complication classification 0.023
 None 301 (83.4%) 326 (90.3%)
 Infectious complications 43 (11.9%) 25 (6.9%)
 Non-infectious complications 17 (4.7%) 10 (2.8%)
Post-operative complication severityc 0.006
 None 301 (83.4%) 326 (90.3%)
 Grade II 38 (10.5%) 23 (6.4%)
 Grade III or greater 22 (6.1%) 12 (3.3%)
Transferring to ICU post-operation 16 (4.4%) 11 (3.0%) 0.327
Post-operative hospital stays (days) 13.20 ± 10.70 12.34 ± 4.05 0.153

Data are presented as mean ± SD or n (%)

ASA American Society of Anesthesiology, ICU intensive care unit

aIncluding pyloric obstruction or bleeding

bTumor stages are based on 7th edition of the Union for International Cancer Control TNM classification

cBased on the Clavien–Dindo severity classification of surgical complications